WORCESTER, Mass., Feb. 23, 2011 /PRNewswire/ — Generex
Biotechnology Corporation (www.generex.com) (OTC Bulletin
Board:
GNBT) announced today that Stamford Hospital has agreed to
participate in the United States Food and Drug Administration (FDA)
Expanded Access Treatment Investigational New Drug (IND) Program
for Generex Oral-lyn™, the Company’s proprietary buccal
insulin spray product for the treatment of patients with
diabetes.
(Logo:
http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)
Stamford Hospital (www.stamfordhospital.org)
is a not-for-profit provider of comprehensive healthcare services
in Connecticut. The mission of Stamford Hospital is to
provide, together with its physicians, a broad range of high
quality health and wellness services focused on the needs of the
communities it serves. Stamford Hospital is a member of the
Planetree Alliance, a group of hospitals nationwide focused on
patient-centered care. Stamford Hospital is affiliated with
the New York Presbyterian Health System and is a major teaching
affiliate of the Columbia University College of Physicians and
Surgeons.
The successful opening of Stamford Hospital’s Diabetes and
Endocrine Center in 2008, housing its Endocrinology practices,
first of Dr. Anna C. Freitag M.D., F.A.C.P., F.A.C.E., M.A.C.D.S.,
C-MC, Medical Director, and most recently of Dr. Bismruta Misra
M.D., M.P.H., as well as an established Diabetes Education Program,
was an organizational strategic initiative developed and supported
by Stamford Hospital. The medical staff at the Diabetes and
Endocrine Center provides exemplary care and treat a full range of
diabetes and endocrine conditions and disorders. The Diabetes
Self Management Education Program, established in 2002, provides
quality diabetes educat
‘/>”/>
SOURCE
